-

Simulations Plus to Present at Oppenheimer Healthcare Conference

LANCASTER, Calif.--(BUSINESS WIRE)--Simulations Plus, Inc. (Nasdaq: SLP), a premier provider of simulation and modeling software and consulting services for pharmaceutical discovery and development, today announced that Shawn O’Connor, chief executive officer, will be presenting at Oppenheimer’s 31st Annual Healthcare Conference on Tuesday, March 16, 2021. Mr. O’Connor’s presentation, which will be webcast live, will begin at 2:30 p.m. ET. In addition, Mr. O’Connor and chief financial officer Will Frederick will host one-on-one meetings throughout the day.

The Company’s slide presentation will be available on the Investors page of the Simulations Plus website following the presentation. For more information about the Oppenheimer Annual Healthcare Conference, or to register to attend, please visit the conference website.

About Simulations Plus, Inc.

Simulations Plus, Inc., is a leading provider of modeling and simulation software and consulting services supporting drug discovery, development research, and regulatory submissions. With our subsidiaries, Cognigen, DILIsym Services, and Lixoft, we offer solutions which bridge machine learning, physiologically based pharmacokinetics, quantitative systems pharmacology/toxicology, and population PK/PD modeling approaches. Our vision is to improve health through innovative solutions, and our mission is to create value for our customers by accelerating and reducing the costs of R&D through innovative science-based software and consulting solutions that optimize treatment options and improve patient lives. For more information, please visit our website at www.simulations-plus.com.

Contacts

Simulations Plus Investor Relations
Ms. Renee Bouche
661-723-7723
renee@simulations-plus.com

Hayden IR
Mr. Cameron Donahue
651-653-1854
slp@haydenir.com

Simulations Plus, Inc.

NASDAQ:SLP

Release Summary
Simulations Plus CEO Shawn O'Connor will present at Oppenheimer's 31st Annual Healthcare Conference on March 16, 2021, beginning at 2:30 p.m. ET.
Release Versions

Contacts

Simulations Plus Investor Relations
Ms. Renee Bouche
661-723-7723
renee@simulations-plus.com

Hayden IR
Mr. Cameron Donahue
651-653-1854
slp@haydenir.com

Social Media Profiles
More News From Simulations Plus, Inc.

Simulations Plus Announces Funded Partnership with Global Pharmaceutical Company to Advance AI-Enabled QSP Model Development with Turin

RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)--Simulations Plus, Inc. (Nasdaq: SLP) (“Simulations Plus” or the “Company”), a global leader in model-informed and AI-accelerated drug development that advances biopharma innovation, today announced a funded partnership with a global large pharmaceutical company to apply Turin, its AI-enabled scientific engine for quantitative systems pharmacology (QSP), within an active therapeutic development program. The collaboration will evaluate how AI-enabled...

Simulations Plus Announces Completion of Acquisition by Altaris

RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)--Simulations Plus, Inc. (Nasdaq: SLP) (“Simulations Plus” or the “Company”), a global leader in model-informed and AI-accelerated drug development that advances biopharma innovation, today announced the completion of its acquisition by affiliates of Altaris, LLC ("Altaris"), an investment firm focused exclusively on the healthcare industry.The transaction was originally announced on June 16, 2026. At the effective time of the merger each Simulations...

Simulations Plus Expands FDA Adoption of ADMET Predictor® with New Licenses for the Cosmetics Regulatory Science Branch

RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)--Simulations Plus, Inc. (Nasdaq: SLP) (“Simulations Plus” or the “Company”), a global leader in model-informed and AI-accelerated drug development that advances biopharma innovation, today announced that the U.S. Food and Drug Administration’s (FDA) Cosmetics Regulatory Science Branch has licensed ADMET Predictor® to support its computational research for modern cosmetic safety assessment. The contract expands the use of Simulations Plus technology...
Back to Newsroom